Clinical Trials Register

Trials with a EudraCT protocol (101)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

101 result(s) found for: Marginal Zone B Cell Lymphoma. Displaying page 4 of 6.

EudraCT Number: 2021-003855-40

Sponsor Protocol Number: MOR208C115

Start Date*: 2022-03-09

Sponsor Name:MorphoSys AG

Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref...

Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-002139-41

Sponsor Protocol Number: R1979-ONC-1625

Start Date*: 2019-09-11

Sponsor Name:Regeneron Pharmaceuticals, Inc.

Full Title: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Medical condition: Follicular lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029547	Non-Hodgkin's lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-005725-24

Sponsor Protocol Number: M22-132

Start Date*: 2022-04-25

Sponsor Name:AbbVie Deutschland GmbH & Co. KG

Full Title: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

Medical condition: B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003903	B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT
	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-001748-36

Sponsor Protocol Number: GCT3013-01

Start Date*: 2018-09-24

Sponsor Name:Genmab A/S

Full Title: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Medical condition: Relapsed, progressive and/or refractory mature B-cell lymphoma Patients with: - Diffuse large B-cell lymphoma – de novo or transformed - High-grade B-cell lymphoma - Primary mediastinal large B...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003903	B-cell lymphoma refractory	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-002044-16

Sponsor Protocol Number: 20150292

Start Date*: 2016-10-04

Sponsor Name:Amgen Inc.

Full Title: A Phase 2/3 Multi-center Study of Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma

Medical condition: Subjects with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10020067	High grade B-cell lymphoma Burkitt-like lymphoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036710	Primary mediastinal large B-cell lymphoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10063908	Non-Hodgkin's lymphoma unspecified histology aggressive	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2004-004349-16	Sponsor Protocol Number:	Start Date*: 2005-11-18
Sponsor Name:GELA Group
Full Title: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined ...
Medical condition: Low grade B-cell lymphoma CD20 positive: -Marginal zone -Lymphocytic -Follicular
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: View results

EudraCT Number: 2020-003999-40

Sponsor Protocol Number: EONHL1-20

Start Date*: 2021-02-09

Sponsor Name:Enterome

Full Title: A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients ...

Medical condition: Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Lymphoma)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029547	Non-Hodgkin's lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2013-004526-28

Sponsor Protocol Number: BMT-CTN#1101

Start Date*: 2015-06-17

Sponsor Name:National Institutes of Health/National Heart, Lung and Bood Institute

Full Title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow ...

Medical condition: patients eligible for a hematopoietic stem cell transplantation with a diagnosis of: 1)Acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia, or Burkitt’s lymphoma in remission. 2)Lym...

Disease:	Version	SOC Term	Classification Code	Term	Level
	16.1	10005329 - Blood and lymphatic system disorders	10025319	Lymphomas Hodgkin's disease	HLGT
	16.1	100000004864	10024330	Leukemia acute	LLT
	16.1	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT
	16.1	10005329 - Blood and lymphatic system disorders	10025321	Lymphomas non-Hodgkin's T-cell	HLGT
	16.1	10005329 - Blood and lymphatic system disorders	10006596	Burkitt's lymphomas	HLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-006049-36

Sponsor Protocol Number: INCMOR0208-305

Start Date*: 2022-06-29

Sponsor Name:Incyte Corporation

Full Title: A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Medical condition: Diffuse large B-cell lymphoma (DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10012883	Diffuse lymphoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-003946-36

Sponsor Protocol Number: TAK-981-1501

Start Date*: 2022-10-07

Sponsor Name:Takeda Development Center Americas, Inc.

Full Title: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Medical condition: Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-006475-42

Sponsor Protocol Number: ICP-CL-00107

Start Date*: 2022-06-15

Sponsor Name:InnoCare Pharma Inc.

Full Title: A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

Medical condition: B-cell malignancies, including only patients with Grades 1-3a FL, MZL, MCL, and CLL/SLL

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults

Gender: Male, Female

Trial protocol: PL (Completed)

Trial results: (No results available)

EudraCT Number: 2018-000444-26

Sponsor Protocol Number: 17-BI-1206-02

Start Date*: 2018-05-02

Sponsor Name:BioInvent International AB

Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractor...

Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) ES (Ongoing) PL (Prematurely Ended) DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2010-019248-37

Sponsor Protocol Number: IILINFL09

Start Date*: 2010-12-30

Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS

Full Title: A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma

Medical condition: Patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2020-003908-14

Sponsor Protocol Number: M-2020-371

Start Date*: 2021-07-07

Sponsor Name:Miltenyi Biomedicine GmbH

Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff...

Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003903	B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003902	B-cell lymphoma recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-001461-16

Sponsor Protocol Number: 4280-003

Start Date*: 2019-02-13

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Medical condition: Hematologic malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10025315	Lymphoma malignant	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-004657-11

Sponsor Protocol Number: VI-Plt-01

Start Date*: 2012-03-30

Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA

Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)

Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10005329 - Blood and lymphatic system disorders	10050245	Autoimmune thrombocytopenia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-004830-81

Sponsor Protocol Number: FIL_BArT

Start Date*: 2015-12-24

Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS

Full Title: A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C v...

Medical condition: Patients with hepatitis C virus-associated indolent B-cell lymphomas

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT
	20.1	10021881 - Infections and infestations	10065051	Acute hepatitis C	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2009-010824-25	Sponsor Protocol Number: DSHNHL 2008-R6	Start Date*: 2010-04-12
Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation-Hämatologie und Onkologie mbH
Full Title: Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-d...
Medical condition: Patients with relapsed or primary progressive aggressive non-Hodgkin's lymphoma. These lymphomas comprise: 1. Follicular lymphoma grade III (FL III°) 2. Diffuse large B cell lymphoma (DLBCL), all v...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: DE (Prematurely Ended)
Trial results: View results

EudraCT Number: 2014-004689-11

Sponsor Protocol Number: MOR208C204

Start Date*: 2016-05-24

Sponsor Name:MorphoSys AG

Full Title: A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who ...

Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012821	Diffuse large B-cell lymphoma recurrent	PT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) DE (Completed) FI (Completed) PT (Completed) FR (Completed) AT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2013-003893-29

Sponsor Protocol Number: BAY80-6946/17067

Start Date*: 2015-06-25

Sponsor Name:Bayer AG

Full Title: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’...

Medical condition: Patients with relapsed indolent B-cell non-Hodgkin's lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029600	Non-Hodgkin's lymphoma recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed) LT (Completed) HU (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BG (Prematurely Ended) LU (Completed) GR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) RO (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Marginal Zone B Cell Lymphoma